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Circulation: Heart Failure
ORIGINAL ARTICLE

Contemporary Management of Cardiogenic
Shock: A RAND Appropriateness
Panel Approach
Alastair G. Proudfoot , MBChB, PhD*; Antonis Kalakoutas , MSc*; Susanna Meade , MBBS†;
Mark J.D. Griffiths , MBBS, PhD†; Mir Basir , DO; Francesco Burzotta , MD, PhD; Sharon Chih , MBBS, PhD;
Eddy Fan , MD, PhD; Jonathan Haft, MD; Nasrien Ibrahim, MD; Natalie Kruit , MBBS, BA; Hoong Sern Lim , MD;
David A. Morrow, MD, MPH; Jun Nakata , MD; Susanna Price , MB, PhD; Carolyn Rosner , RN; Robert Roswell MD;
Mark A. Samaan , MBBS; Marc D. Samsky, MD; Holger Thiele, MD; Alexander G. Truesdell , MD; Sean van Diepen, MD;
Michelle Doughty Voeltz, MD; Peter M. Irving , MBBS, MA
BACKGROUND: Current practice in cardiogenic shock is guided by expert opinion in guidelines and scientific statements from
professional societies with limited high quality randomized trial data to inform optimal patient management. An international
panel conducted a modified Delphi process with the intent of identifying aspects of cardiogenic shock care where there was
uncertainty regarding optimal patient management.
METHODS: An 18-person multidisciplinary panel comprising international experts was convened. A modified RAND/University
of California Los Angeles appropriateness methodology was used. A survey comprising 70 statements was completed.
Participants anonymously rated the appropriateness of each statement on a scale of 1 to 9: 1 to 3 inappropriate, 4 to 6
uncertain, and 7 to 9 appropriate. A summary of the results was discussed as a group, and the survey was iterated and
completed again before final analysis.
RESULTS: There was broad alignment with current international guidelines and consensus statements. Overall, 44 statements
were rated as appropriate, 19 as uncertain, and 7 as inappropriate. There was no disagreement with a disagreement index
<1 for all statements. Routine fluid administration was deemed to be inappropriate. Areas of uncertainty focused panel on
pre-PCI interventions, the use of right heart catheterization to guide management, routine use of left ventricular unloading
strategies, and markers of futility when considering escalation to mechanical circulatory support.
CONCLUSIONS: While there was broad alignment with current guidance, an expert panel found several aspects of care where
there was clinical equipoise, further highlighting the need for randomized controlled trials to better guide patient management
and decision making in cardiogenic shock.
Key Words: consensus ◼ hemodynamics ◼ myocardial infarction ◼ percutaneous coronary intervention ◼ shock, cardiogenic

C

ardiogenic shock (CS) is a clinical syndrome of
inadequate end-organ perfusion due to diminished
cardiac output. CS is a leading cause of mortality
associated with acute myocardial infarction (AMI) and
acute decompensated heart failure.1 Improved access to

reperfusion therapies has had minimal impact on AMI CS
mortality over the last decade,2 and mortality from CS
remains unacceptably high (30%–50%).3,4 Outcomes
in non-AMI CS patients, although less comprehensively
studied, appear to be similarly disappointing.5
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WHAT IS NEW?
• This study uses established RAND methodology
to explore and identify uncertainty regarding strategies proposed in current consensus guidance for
the management of acute myocardial infarction cardiogenic shock.
• The panel comprised experts from a range of specialties involved in the care of cardiogenic shock
patients across the globe, providing perspectives
that reflect management across a range of practice
and health systems.

WHAT ARE THE CLINICAL IMPLICATIONS?
• Despite several consensus statements to guide
practice, uncertainty in optimal management of acute
myocardial infarction cardiogenic shock persists, and
additional randomized controlled data are required to
definitively guide clinical practice to resolve persisting uncertainty and improve patient outcomes.
• These uncertainties further highlight the need for randomized controlled trials in acute myocardial infarction cardiogenic shock specifically relating to the
timing of mechanical circulatory support and the role
of right heart catheterization and associated data to
guide escalation to mechanical circulatory support.

Nonstandard Abbreviations and Acronyms
AMI
acute myocardial infarction
AMI CS	acute myocardial infarction cardiogenic
shock
CICU
cardiac intensive care unit
CS
cardiogenic shock
MCS
mechanical circulatory support
PCI
percutaneous coronary intervention
RHC
right heart catheterization
VA ECMO	venoarterial extracorporeal membrane
oxygenation

Technological advancements have driven improvements
in mechanical circulatory support (MCS) including the
development of percutaneous support devices as adjuncts
to medical therapy to mitigate or reverse end-organ damage and potentially unload the heart. Regionalized systems
of care and local team-based care analogous to that used
in AMI and major trauma are evolving to improve early recognition, access to care, uniformity of escalation and consistency of care.6–8 It is hoped that improved definitions of
CS9 coupled with comprehensive hemodynamic assessment of CS may improve patient selection for advanced
therapies and ultimately mortality.10
The 2017 Scientific Statement from the American
Heart Association11 consolidated available evidence with
expert opinion to define contemporary best management

in CS. Since then, a number of International Committees
have developed guidelines to inform the classification,
diagnosis, and management of CS, with a focus on AMI
CS.7,9,12,13 These guidelines are limited by a paucity of
randomized trial data to definitively guide many aspects
of emergency care in CS. This reflects challenges in
patient recruitment, informed consent, nonstandardized
CS definitions and heterogeneity in presentation of a
complex clinical syndrome.14 Aside from early revascularization (SHOCK trial [Should We Emergently Revascularize Occluded Coronaries in Cardiogenic Shock?]15),
culprit lesion only revascularization (CULPRIT-SHOCK
trial [Percutaneous Coronary Intervention Strategies with
Acute Myocardial Infarction and Cardiogenic Shock]4)
and an absence of benefit from intraaortic balloon support in AMI CS (IABP-SHOCK II trial [Intra-aortic Balloon
Pump Support for Myocardial Infarction with Cardiogenic
Shock II]3), best practices in CS are poorly defined, heterogenous, and often dictated by local resource as well as
operator and institution specific clinical critical thinking.
We assembled an interdisciplinary panel of international experts and conducted a modified Delphi consensus process using modified RAND/University of
California Los Angeles appropriateness methodology
with the intent of identifying aspects of CS care where
equipoise or clinical uncertainty persists despite societal
guidance. Assessment was also made of the appropriateness of other interventions that were either outside
the scope of guidelines and pervade clinical practice.

METHODS
The RAND/University of California Los Angeles (University of
California, Los Angeles) appropriateness method uses a modified Delphi panel approach, combining expert opinion with the
best available evidence and clinical guidance to determine the
appropriateness of specific practices in defined clinical situations
(https://www.rand.org/topics/methodology.html).16 The RAND
method is validated as a means of determining the benefit versus
harm of a given intervention irrespective of cost or resources. It is
particularly useful for areas of uncertainty in which evidence may
be insufficient to guide clinical practice, such as in the management of CS. All data relevant to this study are contained within
this article and are, therefore, freely available.
A web-based questionnaire designed and iterated by a core
group (Dr Proudfoot, A. Kalakoutas, Dr Truesdell, Dr Morrow, Dr
Fan, S. Meade, P.M. Irving, and Dr Griffiths) to address key challenges and uncertainties in the management of CS; this was
further iterated at the panel meeting as described below. A bibliography on CS published after the American Heart Association
Scientific Statement 201711 (search strategy in Figure S1) and
a link to a web-based questionnaire was sent to an 17-person
panel comprising specialties involved in the management of CS,
namely: interventional cardiology, advanced heart failure cardiology) cardiac nursing, cardiac intensive care unit (CICU), and
cardiac surgery. The RAND manual suggests a panel size of 7
to 15 participants to balance the breadth of expertise with the
ability to facilitate flowing discussion.16 We increased this to
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ensure adequate representation across specialities and geographic region and to account for the possibility of no-shows for
the panel. There was no requirement for the bibliography to be
used on completion of the questionnaire. Experts were identified through international meetings and societal membership and
selected from a range of countries to encapsulate potential variable practice in CS globally. Institutional review board approval
was waived given the nature of the study. Panellists were asked
to grade the appropriateness of specific interventions through the
course of admission for AMI CS on a scale of 1 to 9 (where 1–3
is inappropriate, 4–6 is uncertain, and 7–9 is appropriate) via an
online survey. These responses were summarized, anonymized,
and presented at a virtual meeting in January 2021. Ambiguity in
the questionnaire was resolved and areas of disagreement within
responses were discussed; achieving or forcing or consensus
was not the objective of discussion. The moderators (S. Meade,
P.M. Irving, and M.A. Samaan) provided expertise in RAND methodology but did not express opinions on management or vote.
After the meeting, and based on panellist feedback, a second
online survey comprising 69 questions was devised and completed (n=17). The final survey was subdivided into 3 categories:
interventions before primary coronary intervention (22 questions),
clinical markers to guide management and escalation (29 questions), and CS service provision (19 questions).
Several assumptions were made. First, CS was defined
by historical trial entry criteria with severity based on the
recent 2019 Society for Cardiovascular Angiography and
Interventions classification of CS.9 Second, all patients were
assumed to have de novo CS and not decompensated heart
failure with decompensation. Where appropriate, the questionnaire specified AMI CS as the cause if logistical decisions
around percutaneous coronary intervention (PCI) required
consideration. Third, other than those areas addressed in the
survey, the management of CS was assumed to be in line with
current guideline recommendations. Finally, vasoactive drugs
were not prespecified in recognition of the level of evidence to
guide choice beyond norepinephrine as the first line vasopressor (class IIB, level B).17
For each scenario, median scores were calculated with a score
of <3.5 being considered inappropriate, ≥3.5 and <6.5 uncertain,
and ≥6.5 appropriate. We used the validated RAND disagreement
index to define disagreement (disagreement index ≥1) among
panellists using the equation below and the interpercentile range,
defined as the difference in the scores that lie on the 30th and
70th percentile. Any scenario in which disagreement was found
70%ile − 30%ile
was DI =
scored as
70%ile + 30%ile  


2.35 + 1.5 × abs  5 −


 

2
uncertain, regardless of the median score.

RESULTS
Overall, 44 statements were rated as appropriate, 19 as
uncertain and 7 as inappropriate. The disagreement index
was <1 for all statements (Tables 1 through 3), indicating
no disagreement. Individual panellist scoring is outlined
in Tables S1 through S3. This held when responses were
divided by geographic region (N America or Europe) and
specialty (interventional cardiology, heart failure cardiology, or CICU; Table S4).

RAND Panel Cardiogenic Shock

Interventions Before Primary Coronary
Intervention and the Institution of MCS
As soon as was feasible in the context of PCI, it was
deemed appropriate to perform a bedside echocardiogram and activate the local multidisciplinary shock team
to guide optimal patient management (Table 1). A fluid
challenge was judged inappropriate in the context of AMI
CS, aside from right ventricular CS. Other interventions
including central venous access, arterial access, initiation of inopressors and right heart catheterization (RHC)
before PCI were considered uncertain due to the risk of
delaying revascularization. Regarding PCI in AMI CS, culprit vessel only PCI was considered appropriate. Where it
had not been performed pre-PCI, it was deemed appropriate to insert central venous and arterial access and
echocardiography following culprit vessel only PCI and
before CICU transfer.
In the event of deteriorating hemodynamics despite
inopressor support, it was considered appropriate that
the decision to escalate to MCS should be discussed
with the local shock team and conform to a local escalation algorithm. It was rated uncertain whether RHC data
should guide escalation to MCS. In moderate to severe
AMI CS (Society for Cardiovascular Angiography and
Interventions Stage ≥C 9) it was uncertain whether MCS
should be instituted before PCI. Univentricular support
was deemed preferable in situations where available
data suggested univentricular failure or an absence of
significant right ventricular failure. It was considered
appropriate that routine insertion of percutaneous MCS
should involve the use of ultrasound and angiography,
micropuncture for vascular access and, in the context of
venoarterial extracorporeal membrane oxygenation (VA
ECMO), distal perfusion catheters. The routine use of left
ventricular unloading strategies in patients on VA ECMO,
to include an Impella/ECPella or IABP strategy were all
judged as uncertain.

Clinical Markers to Guide Management and
Escalation
Clinical examination, serial serum lactate, echocardiography (if not already performed), hemodynamic
assessment using pulmonary capillary wedge pressure, pulmonary artery saturation, cardiac output/index,
cardiac power output as well as assessment and reassessment of Society for Cardiovascular Angiography
and Interventions CS stage were all considered appropriate post-PCI (Table 2). The use of pulmonary artery
pulsatility index in CS, specifically in the context of congestion or raised right heart pressures, was considered
uncertain.
Regarding hemodynamic or biochemical targets for
patients with CS (both in the presence and absence
of MCS), maintaining a mean arterial pressure of 65
mm Hg and reducing inopressors to maintain this
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Table 1. Interventions Before Primary Coronary Intervention and the Institution of Mechanical Circulatory Support
Statements

Median

DI

IPR

RAND panel
outcome

In a patient presenting with AMI cardiogenic shock manifest with; a systolic BP of ≤85 mm Hg, cool peripheries, a lactate of ≥4 mmol/L and evidence of pulmonary oedema, please rate the appropriateness of the following investigations/interventions on admission and pre-PCI:
Fluid challenge

3

0.04

0.2

Inappropriate

Echocardiography

7

0.22

1.0

Appropriate

Arterial line insertion

4

0.55

2.2

Uncertain

Central venous access

4

0.27

1.2

Uncertain

Hemodynamic stabilization with inopressors

6

0.97

3.0

Uncertain

Right heart catheterization

4

0.52

2.0

Uncertain

Shock team activation

7

0.30

1.2

Appropriate

Regarding percutaneous coronary intervention in AMI CS and management in the catheter lab, please rate the appropriateness of the following:
Culprit vessel only PCI

9

0.16

1.2

Appropriate

Central venous and arterial access before CICU transfer

8

0.19

1.2

Appropriate

Right heart catheterization before CICU transfer to guide MCS strategy

7

0.16

1.0

Appropriate

Echocardiography before CICU transfer if not already performed

7

0.52

2.0

Appropriate

Regarding institution of mechanical circulatory support in AMI CS, please rate the appropriateness of the following:
Institute before PCI in AMI CS SCAI ≥stage C where feasible

5.5

0.52

2.0

Uncertain

Should be guided by right heart catheter data

6

0.27

1.2

Uncertain

Should be guided by a local escalation algorithm

7

0.22

1.0

Appropriate

Ideally should occur after discussion with a local or regional shock team

8

0.16

1.0

Appropriate

Univentricular support is preferred where physiology allows (ie, data is available from RHC or echo)

8

0.16

1.0

Appropriate

8

0.29

2.0

Appropriate

Use of micropuncture

7

0.27

1.2

Appropriate

Routine use of a distal limb/retrograde perfusion catheter for peripheral VA ECMO

8

0.29

2.0

Appropriate

Regarding the insertion of percutaneous mechanical circulatory support, please rate the appropriateness of the following
 Routine use of ultrasound and angiography if patients are sufficiently stable to move to the cardiac catheter lab or hybrid theatre

Regarding routine left ventricular unloading in patients supported with venoarterial ECMO, please rate the appropriateness of the following:
 Use of an LV unloading strategy only where data support its use (LVEDP, echo, refractory pulmonary
oedema)

6

0.52

2.0

Uncertain

Impella strategy

6

0.32

1.0

Uncertain

IABP strategy

5

0.32

1.0

Uncertain

For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate, ≥3.5 and <6.5 uncertain, and ≥6.5 appropriate. DI was
calculated using the validated RAND DI to define disagreement (DI ≥1) among panellists. AMI indicates acute myocardial infarction; BP, blood pressure; CICU, cardiac
intensive care unit; CS, cardiogenic shock; DI, disagreement index; echo, echocardiogram; IABP, intraaortic balloon pump; IPR, interpercentile range; LV, left ventricular;
LVEDP, left ventricular diastolic pressure; MCS, mechanical circulatory support; PCI, percutaneous coronary intervention; RHC, right heart catheterization; SCAI, Society
for Cardiovascular Angiography and Interventions; and VA ECMO, venoarterial extracorporeal membrane oxygenation.

threshold were deemed appropriate. It was also considered appropriate to target a serum lactate <2 mmol/L.
The use of a cardiac index of >2.2 L/(min·m2), cardiac
power output >0.6 W or a pulmonary capillary wedge
pressure <15 mm Hg as treatment thresholds were
deemed uncertain.
Panellists subsequently rated the appropriateness
of a trial of MCS for CS in the presence of putative
markers of futility. It was deemed inappropriate to
institute MCS in cases where there was unequivocal
evidence of anoxic brain injury, active or uncontrolled
bleeding, prohibitive vascular access or shock team
consensus of futility. The institution of short-term
MCS was considered uncertain in patients with a
serum lactate >8 mmoml/L, >30 minutes of cardiopulmonary resuscitation before return of spontaneous

circulation or in patients ineligible for advanced heart
failure therapies.
It was considered appropriate for patients with CS
requiring inopressor and MCS to be managed on a unit
with the requisite expertise including cardiology, cardiac
intensive care, and cardiac surgery. Additionally, it was
considered appropriate to use continuous mixed venous
oxygen saturations (ScVO2) and either continuous or
intermittent cardiac output monitoring to guide titration
and escalation of medical therapies and MCS. Early
consultation with the advanced heart failure team was
recommended in patients failing to demonstrate clinical
or physiological improvements within 72 hours of admission. Failure to improve by this juncture should trigger
transfer to a center with durable ventricular assist device
or transplant capacity in eligible patients.
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Table 2. Clinical Markers to Guide Management and Escalation
Statements

Median

DI

IPR

RAND panel outcome

In patients with cardiogenic shock requiring inopressor and MCS support the following investigations/interventions should be performed routinely during the first
24–48 h:
Clinical examination

9

0.00

0.0

Appropriate

Serum lactate

9

0.02

0.2

Appropriate

Echocardiography if not already performed

9

0.16

1.2

Appropriate

PCWP measurement

7

0.37

2.0

Appropriate

Pulmonary artery saturations

7

0.19

1.2

Appropriate

Continuous ScVO2 and CO measurement

7

0.25

1.2

Appropriate

Assessment and re-assessment of SCAI CS stage

7

0.00

0.0

Appropriate

Assessment of cardiac power output

7.0

0.27

1.2

Appropriate

6

0.27

1.2

Uncertain

 Assessment of pulmonary artery pulsatility index in the context of congestion or elevated right
heart pressures

Please rate the appropriateness of the following hemodynamic/biochemical targets for patients with CS managed with or without MCS:
Mean arterial pressure >65 mm Hg

7

0.42

2.2

Appropriate

Minimize inopressors to maintain a mean arterial pressure >65

7

0.16

1.0

Appropriate

Lactate <2 mmol/L

8

0.16

1.0

Appropriate

PCWP <15 mm Hg

6

0.52

2.0

Uncertain

CI >2.2 L/min/m

6

0.22

1.0

Uncertain

Cardiac power output >0.6 W

6

0.32

1.0

Uncertain

2

Please rate the appropriateness of initiation of a trial of mechanical circulatory support for cardiogenic shock in the presence of the following:
Lactate >8 mmol/L

6

0.52

2.0

Uncertain

Prolonged (>30 min) CPR before ROSC

5

0.15

0.4

Uncertain

Evidence of anoxic brain injury (clinical or imaging)

2

0.29

2.0

Inappropriate

Active/uncontrolled bleeding

2

0.16

1.0

Inappropriate

Prohibitive vascular access

2

0.16

1.0

Inappropriate

Age >80 y

3

0.22

1.0

Inappropriate

Ineligibility for advanced heart failure therapies

5

0.37

1.2

Uncertain

Shock team consensus of futility

2

0.9

1.0

Inappropriate

Regarding the management of patients with cardiogenic shock requiring inopressor and MCS on the CICU please rate the appropriateness of the following:
 Should be managed on a unit with the relevant expertise with input from cardiology, cardiac surgery and intensive care (eg, cardiac intensive care unit)

8

0.13

1.0

Appropriate

Right heart catheter guided management of MCS and/or inopressors

7

0.20

1.2

Appropriate

Early consultation with advanced heart failure team in patients who fail to improve within 72 h

8

0.03

0.2

Appropriate

 Eligible patients who fail to improve within 72–96 h should be transferred to a center with durable VAD/transplant capability

7

0.20

1.2

Appropriate

For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate, ≥3.5 and <6.5 uncertain, and ≥6.5 appropriate. DI
was calculated using the validated RAND DI to define disagreement (DI ≥1) among panellists. CI indicates cardiac index; CICU, cardiac intensive care unit; CO, cardiac
output; CPR, cardiopulmonary resuscitation; DI, disagreement index; IPR, interpercentile range; MCS, mechanical circulatory support; PCWP, pulmonary capillary wedge
pressure; ROSC, return of spontaneous circulation; SCAI CS stage, Society for Cardiovascular Angiography and Interventions cardiogenic shock stage; ScVO2, mixed
venous oxygen saturations; and VAD, ventricular assist device.

CS Service Provision
Panellists considered it highly important for a shock hub
to have onsite access to a complement of allied specialties (Table 3). The importance of the need for onsite
durable ventricular assist device/transplant capacity for
centers managing CS was deemed uncertain. Regarding
the requirements of a putative CS center of excellence,
panellists considered it important to have onsite access
to are range of ancillary services outlined in Table 3. The
importance of the need for a retrieval service or CS coordinator were deemed uncertain.

DISCUSSION
The responses of a multidisciplinary, international panel
of experts suggest there is broad alignment with current
international guidelines and consensus statements, including the most contemporaneous American Heart Association guidance in AMI CS which was published subsequent
to this process.13 Nonetheless, there was uncertainty
regarding the value of several interventions that pervade
contemporary clinical practice, summarized in the Figure.
Contrary to the class 1C recommendation of the
European Society of Cardiology guidance,17 the
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Table 3. Cardiogenic Shock Service Provision
Statements

Median

DI

IPR

RAND panel outcome

How important is it to have the following specialties present as the minimum clinical requirement of a cardiogenic shock hub
Interventional cardiology

9

0.00

0.0

Appropriate

Advanced heart failure cardiology

9

0.02

0.2

Appropriate

Durable VAD service and heart transplantation

6

0.55

2.2

Uncertain

Cardiac surgery

9

0.02

0.2

Appropriate

Cardiac intensive care

9

0.00

0.0

Appropriate

Electrophysiology

7

0.23

1.4

Appropriate

Structural heart cardiology

7

0.23

1.4

Appropriate

Vascular surgery

7

0.04

0.2

Appropriate

Palliative care

7

0.40

2.2

Appropriate

How important is it to include the following as service requirements in a cardiogenic shock center of excellence?
Multi-professional shock team

9

0.13

1.0

Appropriate

24/7 MCS capability

9

0.00

0.0

Appropriate

Routine use of escalation algorithms

7

0.20

1.2

Appropriate

Dedicated cardiogenic shock coordinator

6

0.27

1.2

Uncertain

Access to a range of short-term MCS devices (univentricular, biventricular, left and right)

8

0.13

1.0

Appropriate

Retrieval service to support regional referrals

6

0.27

1.2

Uncertain

Contribution to a local, regional or national registry

7

0.40

2.2

Appropriate

Established research infrastructure

7

0.37

2.0

Appropriate

Capability to recruit patients into clinical trials in CS

7

0.30

1.4

Appropriate

Regular network meetings with leads from referral sites

7

0.20

1.4

Appropriate

>20 short-term MCS cases per annum

8

0.29

2.0

Appropriate

For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate, ≥3.5 and <6.5 uncertain, and ≥6.5 appropriate. Disagreement index was calculated using the validated RAND DI to define disagreement (DI ≥ 1) among panellists. CS indicates cardiogenic shock; DI, disagreement index;
IPR, interpercentile range; MCS, mechanical circulatory support; and VAD, ventricular assist device.

institution of a fluid challenge before PCI or hemodynamic assessment was deemed inappropriate.
Although one-third of CS patients are euvolemic and
may increment stroke volume with fluid administration,18 the panel felt that the absence of hypovolemia
was a criterion of CS, and additional fluid administration
may worsen hemodynamics before PCI. This statement
was qualified with the view that fluid administration was
appropriate in isolated right ventricle infarction and CS.
The equipoise regarding the need for hemodynamic
stabilization with continuous infusion vasopressors and
associated arterial and venous access, before PCI was
underpinned by the recognition that timely revascularization is one of few evidenced based interventions in
CS.15 PCI should occur without delay given the impact
on mortality of even minor delays to revascularization.19,20 Hence, hemodynamic stabilization with associated vascular access could occur concomitantly either
in or en-route to the catheter lab.
There was agreement that echocardiography and
shock team activation were appropriate as soon as was
practicable without inappropriate delay to primary revascularization in accordance with consensus guidance.7,11,12
Urgent echocardiography is essential to identify complications requiring intervention as well as to identify
isolated left, right, or biventricular involvement.10,21 Early

consultation with a local shock team may incur a brief
delay to revascularization; however, the panel felt that in
cases where MCS was being considered, team-based
decision making was essential to optimize device timing
and selection and to begin planning longitudinal patient
care including palliative care where intervention was
likely to be futile.
There exists a weak evidence base for MCS in modifying outcome in CS overall. Recent observational data
have suggested that early MCS implementation in CS
may improve systemic and coronary perfusion and
reduce cardiac work as well as mitigate the risks of multiorgan failure.11,22 Consistent with concerns about delays
to revascularization, in the absence of data from ongoing clinical trials, the panel highlighted concerns regarding delays to evidence-based reperfusion therapy with
implementation of pre-PCI MCS. Although, left ventricular unloading in ST-segment elevation myocardial infarction without CS for 30 minutes pre-PCI may be safe,
neither the use of percutaneous microaxial univentricular
support or the intraaortic balloon pump pre-PCI confer
clear clinical benefit.23,24 Regardless of timing, there was
consensus that institution of MCS should be guided by
local escalation algorithms with input from the shock
team and that a univentricular support strategy was preferable where hemodynamic data were supportive.
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Figure. Management algorithm summarizing RAND panel recommendations in acute myocardial infarction cardiogenic shock
(AMI CS).
CICU indicates cardiac intensive care unit; CPR, cardiopulmonary resuscitation; CI, cardiac index; CO, cardiac output; CPO, cardiac power
output; CS, cardiogenic shock; CVC, central venous catheter; DPC, distal perfusion cannula; IABP, intra aortic balloon pump; HF, heart failure;
LV, left ventricular; MAP, mean arterial pressure; MCS, mechanical circulatory support; PCI, primary percutaneous coronary intervention;
PCWP, pulmonary capillary wedge pressure; RHC, right heart catheterization; SCAI, Society for Cardiovascular Angiography and Interventions;
ScVO2, mixed venous oxygen saturations; US, ultrasound; VAD, ventricular assist device; and VA ECMO, venoarterial extracorporeal membrane
oxygenation.

Observational data suggest that a RHC guided
approach may improve survival in AMI CS25,26 despite
prior study suggesting no benefit.27 Current guidelines
and scientific statements propose RHC use in the management of CS patients unresponsive to initial therapy or
where there is diagnostic or therapeutic uncertainty. While
escalation algorithms focus on elevated left ventricular
end-diastolic pressure in the context of low cardiac output as a trigger for MCS deployment,25,26 panellists had
equipoise regarding routine RHC use in the initial prePCI assessment of CS in the catheter lab to guide emergent MCS pre-PCI. RHC data may allow identification/
confirmation of right heart dysfunction which can impact
both MCS configuration and prognosis.10,28 The use of
RHC to guide management of refractory shock including
fluid management, titration of inopressors, and escalation/de-escalation of MCS on the CICU was, however,
advocated and the panel felt that RHC insertion immediately before CICU transfer or on CICU admission was

appropriate. The utility of continuous ScVO2 and either
continuous or intermittent cardiac output to guide titration and escalation/de-escalation of both pharmacological and mechanical support therapies was highlighted.
There was uncertainty regarding the value of pulmonary
artery pulsatility index, specifically in the presence of elevated right-sided heart pressures. Despite a small attendant risk pulmonary artery perforation/hemorrhage with
pulmonary capillary wedge pressure measurement, there
was agreement that this should be serially performed
daily and targeted according to local algorithms using
pulmonary artery diastolic pressure used as a surrogate
in the intervening period.
For the hemodynamic and clinical benefits of MCS to
manifest, complications from large-bore vascular access,
including bleeding, must be offset. Recent registry data
have highlighted increased rates of vascular injury, major
bleeding and in-hospital death in AMI CS patients.29–33
Predicated by recognition for needed improved safety to
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improve outcome in CS, the panel deemed it appropriate
that percutaneous MCS insertion should be guided by
a combination of micropuncture access guided by ultrasound, fluoroscopy, and angiography. Safety approaches,
specifically bundles of vascular access care, require formative assessment through innovative randomized controlled trials. In the context of peripheral VA ECMO, which
has a larger arterial cannula size than most percutaneous
support devices, routine use of distal perfusion catheter
was deemed appropriate, based on high rates of limb
ischemia and observational data suggesting this can be
minimized with distal perfusion catheter use.34,35
Panellists were uncertain regarding left ventricular unloading strategies in the context of peripheral VA
ECMO. International practice is heterogenous regarding
both timing and unloading device strategy with potential for increased complications associated with multiple MCS devices. Nonetheless, a recent meta-analysis
of observational studies identified expedited weaning
from VA ECMO and improved short-term mortality with
a venting strategy, particularly if instituted in the first
12-hours.36 Further, in propensity matched patients
with predominantly AMI CS supported with VA ECMO,
there was 21% absolute reduction in 30-day mortality in
patients unloaded with an Impella device (Abiomed, Danvers, MA) compared with no unloading, despite increased
complications in the unloaded cohort.37
Given the resource implications of MCS deployment,
the development of prognostic markers and risk scores
to identify futility is desirable and should be a priority for
future research.11 The use of a lactate >8 mmol/L and
cardiopulmonary resuscitation duration of >30 minutes
were deemed as uncertain metrics of futility. Lactate
dynamics are likely to be more prognostically valuable
than a single, point of entry measurement.38 While anoxic
brain injury was deemed to be an acceptable metric of
futility, at least for escalation to interventional therapies,
it was recognized that there are significant uncertainties around assessment and prognostication in the acute
phases of shock and cardiac arrest. Similarly, duration
of resuscitation presented uncertainty given that survival with good neurological outcome occurs in 8% of
patients even after 30 minutes of resuscitation.39 There
was agreement that single parameters such as these in
isolation are unlikely to define escalation decisions.
Recent observational data from North America have
proposed benefit of protocolized escalation of care
through the implementation of CS hubs within a network
of care supporting referring spoke centers.6,8,25 Panellists substantiated guideline-based recommendations to
develop such systems of care with uncertainty regarding a mandate for durable MCS and transplantation to
be located at a CS hub and the requirement for a CS
coordinator. In many health care systems, access to
advanced heart failure therapies is supra-regionalized.
The panel deemed that geographically strategic CS hubs

RAND Panel Cardiogenic Shock

(without durable MCS and transplant) to optimize patient
and referrer access was an unmet need whereas multiple small volume centers was less so, albeit that close
collaboration between the 2 would be essential. Notably, research infrastructure and the capability to recruit
patients into prospective clinical trials was accepted as a
prerequisite of a CS center of excellence.
The current focus of current or planned randomized
clinical trials in CS is the role of MCS devices to improve
mortality. The data presented herein, suggest that there
remains either uncertainty regarding aspects of AMI CS
care such as the timing of RHC, translating hemodynamic
parameters into optimal therapeutic intervention, left ventricle unloading strategies and markers of futility or clinician
confidence in aspects of care where there is limited evidence base such as vascular access and the role of local
shock teams and local escalation algorithms. While trials in
CS remain challenging, efforts to address these knowledge
gaps leveraging novel trial designs and collaborations with
industry and regulators are required to better inform future
consensus guidelines and clinical practice alike. The Cardiac Safety Research Consortium Think Tank14 and Critical
Care Clinical Trialists Workshop40 are 2 such collaborations
working to address these challenges.
The major strength of our study was engagement of
specialists from a range of disciplines and from a broad
scope of international practice using rigorous methodology to combine the best available evidence with the
clinical expertise of the panel. We acknowledge several
limitations. RAND panels interrogate the appropriateness
of an intervention, regardless of available resources. Many
of the proposed interventions and service developments
within guidelines and substantiated herein are expensive
and their use is restricted in resource-limited health care
systems. The process was agnostic to MCS device reflecting the absence of evidence base for specific devices and
the variable availability across health care systems of different MCS modalities. It was impossible to encompass all
scenarios encountered in clinical practice. We focussed
on AMI CS because it is the phenotype most comprehensively covered by consensus guidance with clear patient
pathways that are broadly similar across health care systems. While there is overlap, the conclusions drawn here
are of limited value in the management of acute decompensated heart failure. A RAND analysis of acute decompensated heart failure CS management may have future
value to delineate uncertainties in the management of this
important cohort. Finally, shared decision making in CS
should always consider patient (and family) wishes which
are not discussed herein.
To conclude, this RAND panel provides further realworld guidance on the perceived best practices for
management of AMI CS. A multidisciplinary panel supported many of the recommendations of current guidelines and consensus statements. Nonetheless, the panel
also identified areas of care where uncertainty persists,
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specifically in pre-PCI interventions, the role of RHC
as a precursor to MCS pre-PCI, derived hemodynamic
parameters to guide management and optimal left ventricle unloading strategies. Based on the results, several
research priorities were identified that may be integrated
into current and future clinical trials.
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